News | Pharmaceuticals | July 10, 2023

FDA Approves Expanded Indication for Leqvio

Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not had a cardiovascular event but are at an increased risk of heart

Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not had a cardiovascular event but are at an increased risk of heart

July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy1. This patient population includes those who have comorbidities such as hypertension and diabetes and have not yet had a first cardiovascular event2

"Novartis is committed to addressing the rising burden of cardiovascular disease, a substantial public health burden affecting 30 million Americans," said Victor Bulto, President of Novartis Innovative Medicines US. "High LDL-C is one of the most readily modifiable risk factors for heart disease and this label update for Leqvio will help us reach a greater number of patients who struggle with lowering their LDL-C." 

Initially approved by the FDA in December 2021, Leqvio is the first and only small interfering RNA (siRNA) therapy to lower LDL-C. The updated indication for primary hyperlipidemia allows for the expanded use of Leqvio as an adjunct to diet and statin therapy beyond the previously approved atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) patient populations1

With two doses a year, after two initial doses, Leqvio was proven to provide powerful and consistent LDL-C lowering of up to 52% vs. placebo for patients with heart disease or at increased risk of heart disease, who were unable to reach their LDL-C target despite statin therapy1,3,4. After administration of Leqvio by a health care provider (HCP), HCPs can be confident that a dose won't be missed for 6 months1

Other updates to the label include the removal of the Limitations of Use statement and the safety section was streamlined to remove four adverse events since the frequency of these events were the same as the placebo arm. Effective immediately in the US, this label update reinforces the robust safety and effectiveness data for Leqvio that are being generated by the VictORION clinical trial program. VictORION is one of the largest cardiovascular clinical trial programs with more than 20 trials and is designed for consistent and comprehensive data generation. 

For more information: www.novartis.us

References 

  1. Leqvio prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2023. 
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486 
  3. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387   
  4. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. doi:10.1056/NEJMoa1913805  
  5. Heart disease facts. Centers for Disease Control and Prevention; 2020. Accessed June 23, 2023. https://www.cdc.gov/heartdisease/facts.htm 
  6. Goldstein JL, Brown MS. A Century of Cholesterol and Coronaries: from Plaques to Genes to Statins. Cell. 2015;161(1):161–172. doi: 10.1016/j.cell.2015.01.036 
  7. World Health Organization (WHO). Cardiovascular diseases (CVDs); 2021. Accessed June 23, 2023. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) 
  8. Arnett D, Blumenthal R, Albert M, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678 
  9. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829-1830. doi:10.1001/jama.2021.5469 
  10. Centers for Disease Control and Prevention. Vital Signs: Preventing 1 Million Heart Attacks and Strokes; 2018. Accessed June 23, 2023. https://www.cdc.gov/vitalsigns/million-hearts/index.html

Related LDL-lowering Drug News:

FDA Clears Novartis Inclisiran to Lower Cholesterol With Only Two Doses a YearVIDEO: Novel Therapeutics for Lowering Lipids — Interview with Susan Cheng, M.D.

Inclisiran Reduced LDL-C in Obese Patients

New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender

Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials

What Trends are Ahead in Cardiovascular Medicine in 2018?

VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies

ORION 1 Trial Shows Inclisiran Lowers Bad Cholesterol Up to One Year

Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials

FDA Clears Bempedoic Acid Non-statin LDL-cholesterol Lowering Drug


Related Content

News | Pharmaceuticals

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

Home July 10, 2024
Home
News | Pharmaceuticals

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
News | Pharmaceuticals

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

Home May 24, 2024
Home
News | Pharmaceuticals

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

Home May 06, 2024
Home
News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
News | Pharmaceuticals

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
Feature | Pharmaceuticals | By Christine Book

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

Home October 25, 2023
Home
Videos | Pharmaceuticals

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
Subscribe Now